Nassir Marrouche, HRS 2019 – the CASTLE-AF Trial
Dr Nassir Marrouche (Executive Director, CARMA Center, University of Utah, Salt Lake City, UT, USA) spoke to us at Heart Rhythm 2019 on the ablation outcomes from the Catheter Ablation vs. Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE AF) trial, along with the current unmet needs in catheter ablation and his highlights from the meeting.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Nassir Marrouche has received consultancy fees from Abbott, Biosense Webster, Biotronic, Boston Scientific, Marrek Inc., Medtronic, Preventice and Vytronus, and received research grants from Abbott, Biosense Webster, Biotronic, Boston Scientific, GE Healthcare, Siemens and Vytronus. He has company interest in Marrek Inc. and Cardiac Design.
Questions:
1. What were the key findings of the Catheter Ablation vs. Standard Conventional Treatment in Patients with LV Dysfunction and AF (CASTLE-AF) trial? (0:06)
2. How should the benefits shown in CASTLE-AF, including mortality reduction and quality of life improvement, influence patient management and current practice in atrial fibrillation and heart failure? (1:08)
3. What are your highlights from Heart Rhythm 2019? (2:16)
4. What are the current unmet needs in catheter ablation? (3:34)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.